Epifast 750mg Tablet contains Levetiracetam, an anticonvulsant agent used primarily in the management of epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting abnormal neuronal excitability and reducing seizure activity. Epifast is indicated as adjunctive therapy for partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults, adolescents, and pediatric patients aged 4 years and above. The 750mg dosage provides an effective therapeutic option tailored to individual patient needs, often adjusted based on clinical response and tolerability. Epifast is generally well tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue, with serious neuropsychiatric events being rare but warranting monitoring. It has a favorable pharmacokinetic profile with rapid absorption, minimal protein binding, and renal excretion, necessitating dose adjustments in patients with renal impairment. Epifast does not induce or inhibit hepatic enzymes, reducing the risk of drug interactions. It should be administered consistently, with or without food, and discontinuation should be gradual to minimize seizure recurrence. Regular clinical evaluation and monitoring are recommended to optimize therapeutic outcomes and ensure patient safety during treatment with Epifast 750mg Tablet.